Vertex Pharmaceuticals Acquires Crinetics for $10 Billion, Expanding Endocrinology Portfolio

According to Vertex Pharmaceuticals' announcement, Vertex agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash in Q3 2026. The deal values Crinetics at $8.8 billion excluding cash consideration. Each share is priced at $85, representing a 102% premium to Crinetics' Monday closing price. The acquisition aims to expand Vertex's endocrinology business with treatments for acromegaly and hormonal disorders. Both boards have approved the transaction, and Vertex expects the deal to be accretive to adjusted operating income by 2029.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments